WilmerHale Advising AVEO Oncology in Sale to LG Chem

WilmerHale Advising AVEO Oncology in Sale to LG Chem

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
WilmerHale is advising AVEO Oncology on its pending sale to LG Chem in an all-cash transaction with an implied equity value of approximately $566 million. Headquartered in Massachusetts, AVEO Oncology is a biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. In 2021, AVEO Oncology received FDA approval for FOTIVDA® (tivozanib), the first therapy approved for adult patients with relapsed or refractory advanced renal cell carcinoma. 
 
Based in Seoul, South Korea, LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials and life sciences.
 
The WilmerHale team advising AVEO Oncology includes Cynthia Mazareas, Joseph Conahan, JC Minko, Ryan Brewer, Milan Kumar and Virginia Pavlick.

Read more.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel